Drs Nicholas Silvestri and James "Chip" Howard discuss newer and novel myasthenia gravis tools to personalize treatment, including complement inhibitors, FcRn antagonists, biomarkers, and more.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/990460). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) https://clinicaltrials.gov/ct2/show/NCT01997229

Safety and Efficacy of Eculizumab in Anti-acetylcholine Receptor Antibody-positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-blind, Placebo-controlled, Multicentre Study https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30369-1/fulltext

ULTOMIRIS® (Ravulizumab-cwvz) Approved in the US for Adults With Generalized Myasthenia Gravis https://www.astrazeneca-us.com/media/press-releases/2022/ultomiris-approved-in-the-us-for-adults-with-generalized-myasthenia-gravis.html

UCB Announces US FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients https://www.prnewswire.com/news-releases/ucb-announces-us-fda-acceptance-of-new-drug-application-and-ema-maa-validation-for-zilucoplan-for-the-treatment-of-generalized-myasthenia-gravis-in-adult-patients-301676223.html

Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–positive Generalized Myasthenia Gravis https://www.tandfonline.com/doi/full/10.1080/13543784.2021.1897567